Improving HIV treatment options for youth
Strategies to AchieVe Viral Suppression for Youth With HIV (The SAVVY Study)
This study is testing if personalized treatment options and counseling can help young people with HIV better manage their condition and improve their health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 288 (estimated) |
| Ages | 12 Years to 30 Years |
| Sex | All |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT06886971 on ClinicalTrials.gov |
What this trial studies
The SAVVY Study focuses on enhancing viral suppression in adolescents and young adults living with HIV by optimizing their antiretroviral treatment choices. It employs CHOICE counseling to engage participants in shared decision-making regarding their preferred treatment options, including long-acting injectable antiretroviral therapies. The study addresses unique challenges faced by this population, such as cognitive development and psychosocial factors, to improve adherence and health outcomes. By providing tailored interventions and access to alternative treatment strategies, the study aims to significantly improve virologic outcomes for participants.
Who should consider this trial
Good fit: Ideal candidates for this study are adolescents and young adults aged 12-30 who are prescribed antiretroviral therapy and are willing to engage in shared decision-making about their treatment.
Not a fit: Patients with relevant drug resistance mutations, severe mental health issues, or those planning to relocate within the next year may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved viral suppression rates among adolescents and young adults with HIV, enhancing their overall health and reducing public health risks.
How similar studies have performed: Other studies have shown promise in improving treatment adherence and outcomes for youth with HIV using similar engagement and treatment strategies, indicating that this approach is both relevant and potentially effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * prescribed ART, * willing to sign informed consent (including communication with one's primary HIV provider) Exclusion Criteria: * Relevant drug resistance mutations (per medical record) that compromises activity of Cabotegravir (CBG) + rilpivirine (RPV) * disallowed medications, * pregnancy. * Mental health, cognitive, or behavioral dysfunction that in the opinion of the site PI would impair participation; * severe illness/hospitalization at the time of enrollment, * plan to move away in the next 12 months.
Where this trial is running
Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Allison Agwu, MD, SCM — Johns Hopkins University
- Study coordinator: Allison Agwu, MD, SCM
- Email: ageorg10@jhmi.edu
- Phone: 410-614-3917
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.